Antibodies to human programmed death receptor PD-1
AssigneeMerck Sharp & Dohme Corp.
InventorsGregory John Carven, Hans Van Eenenneem, Gradus Johannes Dulos
Life of this patent
Estimating the term…
Abstract
Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
Claims3
A composition comprising an antibody in combination with a pharmaceutically acceptable carrier or diluent, wherein said antibody binds to human PD-1 and comprises:
- a heavy chain comprising amino acid residues 20 to 466 of SEQ ID NO:
- 31;
- and
- a light chain comprising amino acid residues 20 to 237 of SEQ ID NO:
- 36.
A composition comprising an antibody in combination with a pharmaceutically acceptable carrier or diluent, wherein said antibody binds to human PD-1 and comprises:
- a light chain comprising CDRs of SEQ ID NOs 15, 16 and 17;
- and
- a heavy chain comprising CDRs of SEQ ID NOs 18, 19 and 20.
A composition comprising an antibody in combination with a pharmaceutically acceptable carrier or diluent, wherein said antibody binds to human PD-1 and comprises:
- a heavy chain variable region comprising amino acid residues 20 to 139 of SEQ ID NO:30;
- and
- a light chain variable region comprising amino acid residues 20 to 130 of SEQ ID NO:32.
Dependencies are inferred from the claim text.